Related Experiment Video
Updated: Jul 20, 2026
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Emerging drugs for hepatocellular carcinoma
Lewis R Roberts1, Gregory J Gores
1Mayo Clinic College of Medicine, Miles and Shirley Fiterman Center for Digestive Diseases, 200 First Street SW, Rochester, MN 55905, USA. Roberts.Lewis@mayo.edu
Expert Opinion on Emerging Drugs
|August 31, 2006
Summary
Targeted therapies show promise for advanced hepatocellular carcinoma (HCC) by inhibiting key cancer pathways. Combining these treatments with liver disease management is crucial for long-term patient survival.
Area of Science:
- Oncology
- Molecular Biology
- Hepatology
Background:
- Hepatocellular carcinoma (HCC) is frequently diagnosed at advanced stages, limiting curative treatment options.
- Effective chemotherapy for HCC is currently lacking.
- Cancer biology research identifies critical signaling pathways driving uncontrolled cell proliferation in HCC.
Purpose of the Study:
- To review novel anticancer agents targeting key signaling pathways in hepatocellular carcinoma.
- To discuss the potential of these targeted therapies for patients with intermediate and advanced HCC.
- To highlight the necessity of integrating liver disease management with targeted therapies for improved long-term survival.
Main Methods:
- Review of recent advances in cancer biology and molecular signaling pathways implicated in HCC.
- Identification and categorization of novel anticancer agents targeting specific pathways.
- Analysis of the role of chronic liver disease and cirrhosis in HCC patient outcomes.
Main Results:
- Several critical signaling pathways (e.g., receptor tyrosine kinase, Wnt/beta-catenin, PI3K/AKT/mTOR, angiogenic pathways) are implicated in HCC.
- Novel targeted agents show promise for improving outcomes in intermediate and advanced HCC.
- Chronic liver disease significantly impacts HCC progression and necessitates integrated treatment strategies.
Conclusions:
- Targeted anticancer therapies offer a promising new avenue for treating hepatocellular carcinoma.
- Long-term survival in HCC patients, particularly those with underlying cirrhosis, requires a dual approach combining targeted therapies with chronic liver disease reversal strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:16Hepatic Drug Excretion: Influencing Factors
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...